Kolabtreeを選ぶ理由

開始はすばやく簡単です。初期費用はかかりません。

サービス依頼と専門家への見積依頼は無料です。

Kolabtree の作業範囲に同意する前に、専門家と要件を詳しく相談できます。

専門家と直接連携し、必要な成果を正しく得られます。

専門家を採用したらプロジェクトに資金を入れ、作業完了後に成果物を承認できます。

Sasha B. に連絡

連絡する

Kolabtreeを選ぶ理由

この専門家をプロジェクトに採用したいですか？見積もりを依頼無料で。

プロフィール詳細

プロジェクトを作成

★★★★★

☆☆☆☆☆

★★★★★

☆☆☆☆☆

Dr. Sasha B.に依頼

United States

MD/PhD/MBA | Translational Research, Clinical Development & Trial Design: Neurology, Immunology, Genetics & Rare Diseas

プロフィール概要

I am a physician-scientist and Executive Medical Director with 25 years of experience spanning academic research, translational medicine, and pharmaceutical drug development. Deep expertise in early-phase drug development and clinical trial design across neurology, genetics, obesity, immunology, and cell & gene therapy, with a track record of advancing programs from preclinical discovery through Phase 1–3 clinical trials and regulatory submission.

As a life science consultant, I bring R&D expertise to help organizations achieve the best outcomes from their research, communicate findings effectively (data interpretation), saving time and energy along the way.

As a clinical research consultant, I offer hands-on expertise in clinical trial design, protocol writing, literature reviews, and analytical support to help teams get the best outcomes from their research. Extensive medical writing experience, including clinical trial protocols, investigator brochures, informed consent forms, clinical study reports, regulatory submissions (INDs, CTAs, briefing books), manuscripts, and abstracts. Skilled at translating complex scientific and clinical data into clear, well-structured documents for regulatory agencies, executive leadership, and scientific audiences, with a strong foundation in translational research built through years of hands-on laboratory investigation and hypothesis-driven experimentation. Experienced in protocol design, literature review and analysis, medical monitoring, and biostatistics collaboration, combining scientific rigor with precise, audience-appropriate writing to support research communication, publication, and regulatory strategy from early development through market launch.

専門分野

サービス

Writing
Research
Consulting
Data & AI
Product Development

Writing Clinical Trial Documentation, Medical Writing, Non-Medical Regulatory Writing, Technical Writing, Business & Legal Writing, Copywriting, Creative Writing, Newswriting, General Proofreading & Editing, Translation

Research Meta-Research, Feasibility Study, Fact Checking, Gap Analysis, Gray Literature Search, Scientific and Technical Research, Systematic Literature Review, Secondary Data Collection

Consulting Business Strategy Consulting, Healthcare Consulting, Scientific and Technical Consulting

Data & AI Statistical Analysis, Image Processing, Image Analysis, Data Visualization, Big Data Analytics, Data Mining, Data Cleaning, Data Processing, Data Insights

Product Development Concept Development, Product Launch Support

職務経験

Executive Director

Capsida Biotherapeutics (United States)

8月 2025 - 12月 2025

Senior Director

Keros Therapeutics

3月 2024 - 8月 2025

Associate Medical Director

Atara Biotherapeutics (United States)

7月 2021 - 1月 2024

Senior/Medical Science Liaison

EMD Serono, Inc. (United States)

1月 2019 - 7月 2021

Neuroscience and Neurology

IQVIA (United States)

10月 2017 - 1月 2019

Res. Assistant Professor / Sr. Consultant

Northwestern Medicine

10月 2014 - 10月 2017

Postdoctoral Researcher

University of Chicago

10月 2013 - 10月 2014

Instructor

Roosevelt University

10月 2013 - 6月 2014

Postdoctoral Fellow

University of Kentucky

1月 2010 - 9月 2013

Postdoctoral Fellow/ Research Associate/ Senior/Principal Investigator

University of Pennsylvania

2月 2001 - 1月 2010

Physician & Research/Teaching Associate (Physiology)

University of Novi Sad

10月 1999 - 2月 2001

学歴

M.S. (Psychology)

Centenary College of New Jersey

9月 2023 - 5月 2025

MBA (Business)

Fitchburg State University

3月 2018 - 10月 2020

Ph.D. -Neuroscience (Physiology)

University of Novi Sad

10月 2005 - 4月 2009

M.Sc. (Physiology )

University of Novi Sad

10月 1999 - 9月 2003

M.D. (Faculty of Medicine)

University of Novi Sad

10月 1992 - 10月 1999

認定資格

認定資格の詳細は未入力です。

出版物

JOURNAL ARTICLE

Sasha Bogdanovich, Emidio E. Pistilli, Tejvir S. Khurana (2026). Age-Dependent Effect of Myostatin Blockade in the mdx Mouse Model of Duchenne Muscular Dystrophy (DMD) . Muscles.

Sasha Bogdanovich, Emidio E. Pistilli, Tejvir S. Khurana (2026). Age-Dependent Effect of Myostatin Blockade in the mdx Mouse Model of Duchenne Muscular Dystrophy (DMD) . Muscles.

(2026). ACE-031, a soluble activin type IIB receptor, increases muscle mass and strength in the common marmoset (Callithrix jacchus) . PLOS ONE.

(2025). ACE-031, a Soluble Activin Type IIB Receptor, Increases Muscle Mass and Strength in the Common Marmoset (Callithrix jacchus) . bioRxiv.

(2025). I Cannot Sleep!! . PHYSICIAN ASSISTANT CLINICS.

(2025). Phase 1 Trial in Healthy Participants of KER-065, Modified Activin Receptor Ligand Trap, Support Development in Duchenne Muscular Dystrophy (DMD) and Bone Disorders. JOURNAL OF BONE AND MINERAL RESEARCH.

(2025). Phase 1 trial in healthy participants of KER-065, modified activin receptor ligand trap, support development in DMD and other neuromuscular disorders . NEUROMUSCULAR DISORDERS.

(2024). Confirmed Disability Improvement and Progression in Nonactive Progressive Multiple Sclerosis Patients in a Real-World Registry. MULTIPLE SCLEROSIS JOURNAL.

(2023). A Fully Enrolled, Novel, Patient-Centred Real-World Evidence Study Designed to Better Understand Active and Nonactive Progressive Multiple Sclerosis Using Health Records in the United States. MULTIPLE SCLEROSIS JOURNAL.

(2023). Characterizing Mental and Physical Fatigue in Patients With Active or Nonactive Primary or Secondary Progressive Multiple Sclerosis in the United States. MULTIPLE SCLEROSIS JOURNAL.

(2023). Physical and Psychological Impact in Individuals With Active and Nonactive Primary and Secondary Progressive Multiple Sclerosis in the United States. MULTIPLE SCLEROSIS JOURNAL.

(2023). Physician-reported Cognitive Symptoms in Patients with Active and Nonactive Primary or Secondary Progressive Multiple Sclerosis in a Cross-Sectional Survey in the United States. MULTIPLE SCLEROSIS JOURNAL.

(2023). Treatment Patterns and Unmet Need for Patients with Progressive Multiple Sclerosis in the United States: Survey Results from 2016 to 2021 . NEUROLOGY AND THERAPY.

(2022). A novel, patient-centred real-world evidence study designed to better understand active and non-active progressive multiple sclerosis using health records in the United States. MULTIPLE SCLEROSIS JOURNAL.

(2022). Confirmed disability improvement and sustainability in secondary progressive multiple sclerosis placebo-arm patients. EUROPEAN JOURNAL OF NEUROLOGY.

(2022). Disability Progression and Improvement Among Active and Nonactive Secondary Progressive Multiple Sclerosis Patients in Placebo Arms of Clinical Trials (P1-1.Virtual). NEUROLOGY.

(2022). Disability Progression and Improvement Among Patients With Primary and Secondary Progressive Multiple Sclerosis in Placebo Arms of Clinical Trials. MULTIPLE SCLEROSIS JOURNAL.

(2022). Disability progression of active and nonactive primary and secondary progressive multiple sclerosis patients in the US. EUROPEAN JOURNAL OF NEUROLOGY.

(2022). Treatment Patterns of Patients with Active and Nonactive Primary Progressive Multiple Sclerosis in the United States. MULTIPLE SCLEROSIS JOURNAL.

(2022). Unmet need of current disease-modifying treatments reported by physicians in patients with nonactive secondary progressive multiple sclerosis in the United States. MULTIPLE SCLEROSIS JOURNAL.

(2020). High-throughput identification of post-transcriptional utrophin up-regulators for Duchenne muscle dystrophy (DMD) therapy (vol 10, 2132, 2020) . SCIENTIFIC REPORTS.

(2020). High-throughput identification of post-transcriptional utrophin upregulators for Duchenne muscle dystrophy (DMD) therapy . SCIENTIFIC REPORTS.

(2017). Abnormal Muscle Pathology and Physiology . CARDIOSKELETAL MYOPATHIES IN CHILDREN AND YOUNG ADULTS.

(2016). Human IgG1 antibodies suppress angiogenesis in a target-independent manner . SIGNAL TRANSDUCTION AND TARGETED THERAPY.

(2016). Intravenous immune globulin suppresses angiogenesis in mice and humans . SIGNAL TRANSDUCTION AND TARGETED THERAPY.

(2016). Overexpression of Latent TGFβ Binding Protein 4 in Muscle Ameliorates Muscular Dystrophy through Myostatin and TGFβ . PLOS GENETICS.

(2014). A Mouse Model for Dominant Collagen VI Disorders . JOURNAL OF BIOLOGICAL CHEMISTRY.

(2014). DICER1/Alu RNA dysmetabolism induces Caspase-8-mediated cell death in age-related macular degeneration . PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA.

(2014). Excess SMAD signaling contributes to heart and muscle dysfunction in muscular dystrophy . HUMAN MOLECULAR GENETICS.

(2014). Human therapeutic monoclonal antibodies inhibit corneal neovascularization via FcγRI in a target-independent manner. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE.

(2014). IL-18 is not therapeutic for neovascular age-related macular degeneration . NATURE MEDICINE.

(2014). Intravenous immunoglobulin treatment inhibits choroidal and corneal neovascularization via FcyR1. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE.

(2014). Targeting latent TGFβ release in muscular dystrophy . SCIENCE TRANSLATIONAL MEDICINE.

(2014). The Fc fragments of Bevacizumab or IVIG suppress choroidal neovascularization. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE.

(2013). COL6A3 Protein Deficiency in Mice Leads to Muscle and Tendon Defects Similar to Human Collagen VI Congenital Muscular Dystrophy . JOURNAL OF BIOLOGICAL CHEMISTRY.

(2012). DICER1 Loss and Alu RNA Induce Age-Related Macular Degeneration via the NLRP3 Inflammasome and MyD88 . CELL.

(2012). ERK1/2 activation is a therapeutic target in age-related macular degeneration . PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA.

(2012). Inhibition of Choroidal and Corneal Pathologic Neovascularization by Plgf1-de Gene Transfer . INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE.

(2012). Short-interfering RNAs Induce Retinal Degeneration via TLR3 and IRF3 . MOLECULAR THERAPY.

(2011). Biglycan recruits utrophin to the sarcolemma and counters dystrophic pathology in mdx mice . PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA.

(2011). DICER1 deficit induces Alu RNA toxicity in age-related macular degeneration . NATURE.

(2011). Loss of IL-15 receptor α alters the endurance, fatigability, and metabolic characteristics of mouse fast skeletal muscles . JOURNAL OF CLINICAL INVESTIGATION.

(2011). Targeting the Activin Type IIB Receptor to Improve Muscle Mass and Function in the mdx Mouse Model of Duchenne Muscular Dystrophy . AMERICAN JOURNAL OF PATHOLOGY.

(2010). Differential Expression of Utrophin-A and -B Promoters in the Central Nervous System (CNS) of Normal and Dystrophic mdx Mice . BRAIN PATHOLOGY.

(2010). Pretreatment with a soluble activin type IIB receptor/Fc fusion protein improves hypoxia-induced muscle dysfunction . AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY.

(2009). Long-term activin receptor type IIB inhibition improves strength and function of dystrophic muscle . NEUROMUSCULAR DISORDERS.

(2009). The effects of a soluble activin type IIB receptor on obesity and insulin sensitivity . INTERNATIONAL JOURNAL OF OBESITY.

(2009). Transcriptional and functional differences in stem cell populations isolated from extraocular and limb muscles . PHYSIOLOGICAL GENOMICS.

(2008). Myostatin blockade improves function but not histopathology in a murine model of limb-girdle muscular dystrophy 2C . MUSCLE & NERVE.

(2008). Role of hypoxia in muscle function and muscular dystrophy. FASEB JOURNAL.

(2008). Treatment with a soluble Activin type IIB receptor increases muscle size and strength of dystrophin deficient muscle . NEUROMUSCULAR DISORDERS.

(2007). Identification and characterization of layer-specific differences in extraocular muscle M-bands . INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE.

(2006). Corneal avascularity is due to soluble VEGF receptor-1 . NATURE.

(2006). Role of hypoxia-mediated muscle damage in neuromuscular disorders. NEUROMUSCULAR DISORDERS.

(2005). Myostatin propeptide-mediated amelioration of dystrophic pathophysiology . FASEB JOURNAL.

(2005). Molecular and ultrastructural characterization of adult rat extraocular muscle (EOM) M-lines. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE.

(2005). Structural details of rat extraocular muscles and three-dimensional reconstruction of the rat inferior rectus muscle and muscle-pulley interface . VISION RESEARCH.

(2004). Anti-oxidative response of carbonic anhydrase III in skeletal muscle . IUBMB LIFE.

(2004). Heregulin ameliorates the dystrophic phenotype in mdx mice . PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA.

(2004). Layer-specific differences of gene expression in extraocular muscles identified by laser-capture microscopy . PHYSIOLOGICAL GENOMICS.

(2004). Therapeutics for Duchenne muscular dystrophy: current approaches and future directions . JOURNAL OF MOLECULAR MEDICINE-JMM.

(2003). Three dimensional reconstruction and detailed structural analysis of the extraocular muscle-pulley interface. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE.

(2002). Expression profiling reveals metabolic and structural components of extraocular muscles. JOURNAL OF THE NEUROLOGICAL SCIENCES.

(2002). Expression profiling reveals metabolic and structural components of extraocular muscles . PHYSIOLOGICAL GENOMICS.

(2002). Expression profiling reveals metabolic and structural components of extraocular muscles. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE.

(2002). Functional improvement of dystrophic muscle by myostatin blockade . NATURE.

(2002). Myostatin (GDF8) blockage improves muscle function in MDX mouse. JOURNAL OF THE NEUROLOGICAL SCIENCES.